Dickkopf-1 is regulated by the mevalonate pathway in breast cancer

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Rachner, Tilman D ^a   Göbel, Andy ^a   Thiele, Stefanie ^a   Rauner, Martina ^a   Benad Mehner, Peggy ^a   Hadji, Peyman ^b   Bauer, Thomas ^b   Muders, Michael H ^a   Baretton, Gustavo B ^a   Jakob, Franz ^c   Ebert, Regina ^c   Bornhäuser, Martin ^a,d   Schem, Christian ^e   Hofbauer, Lorenz C ^a,d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ATORVASTATIN; DICKKOPF 1 PROTEIN; MEVALONIC ACID; OSTEOPROTEGERIN; PROTEIN CDC42; RHO FACTOR; RNA; WNT3A PROTEIN; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DKK1 PROTEIN, MOUSE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; IMIDAZOLE DERIVATIVE; PYRROLE DERIVATIVE; SIGNAL PEPTIDE; SMALL INTERFERING RNA; WNT3A PROTEIN, MOUSE;

ARTICLE; BONE DEVELOPMENT; BREAST CANCER; CANCER CELL CULTURE; CHEMICAL REACTION; CONTROLLED STUDY; GERANYLGERANYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MALE; OSTEOBLASTOGENESIS; PROSTATE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TISSUE LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; BONE NEOPLASMS; CYTOLOGY; FEMALE; GENE EXPRESSION REGULATION; L CELL LINE; LYMPHOCYTE ACTIVATION; MCF 7 CELL LINE; METABOLISM; MOUSE; OSTEOBLAST; PATHOLOGY; PRENYLATION; RNA INTERFERENCE; SECONDARY; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CDC42 GTP-BINDING PROTEIN; CELL LINE, TUMOR; DIPHOSPHONATES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPTANOIC ACIDS; HUMANS; IMIDAZOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; L CELLS (CELL LINE); LYMPHOCYTE ACTIVATION; MCF-7 CELLS; MEVALONIC ACID; MICE; OSTEOBLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; PRENYLATION; PYRROLES; RHO FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRIPLE NEGATIVE BREAST NEOPLASMS; WNT3A PROTEIN;

EID: 84896878302     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3616     Document Type: Article

References (35)

1. Green J, Lipton A. Anticancer properties of zoledronic acid. Cancer Invest 2010, 28:944-957. 10.3109/07357907.2010.512598, 20879838.
2. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589. 10.1359/jbmr.1998.13.4.581, 9556058.
3. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003, 9:2643-2658. 10.2174/1381612033453640, 14529538.
4. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003, 9:10-19.
5. Mahtani R, Jahanzeb M. Bisphosphonates as anticancer therapy for early breast cancer. Clin Breast Cancer 2010, 10:359-366. 10.3816/CBC.2010.n.047, 20920980.
6. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, Marth C, ABCSG-12 Trial Investigators Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691. 10.1056/NEJMoa0806285, 19213681, ABCSG-12 Trial Investigators.
7. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R, AZURE Investigators Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011, 365:1396-1405. 10.1056/NEJMoa1105195, 21995387, AZURE Investigators.
8. Hadji P, Frank M, Jakob A, Siebers JW. Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: retrospective analysis results in an unselected single-center cohort. J Bone Oncol 2013, 2:2-10.
9. Fedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, Bottaro DP, Kraus MH, Aaronson SA. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem 1999, 274:19465-19472. 10.1074/jbc.274.27.19465, 10383463.
10. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494. 10.1056/NEJMoa030847, 14695408.
11. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy JD. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008, 112:196-207. 10.1182/blood-2008-01-132134, 2435688, 18305214.
12. Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2009, 24:425-436. 10.1359/jbmr.081104, 19016584.
13. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009, 114:371-379. 10.1182/blood-2008-11-191577, 2714212, 19417213.
14. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clézardin P, Garnero P. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007, 97:964-970. 2360424, 17876334.
15. Bu G, Lu W, Liu CC, Selander K, Yoneda T, Hall C, Keller ET, Li Y. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer 2008, 123:1034-1042. 10.1002/ijc.23625, 3732167, 18546262.
16. Xu WH, Liu ZB, Yang C, Qin W, Shao ZM. Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype. PLoS One 2012, 7:e37624. 10.1371/journal.pone.0037624, 3359298, 22649545.
17. Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 2008, 68:1396-1404. 10.1002/pros.20805, 3260942, 18561248.
18. Stein NC, Kreutzmann C, Zimmermann SP, Niebergall U, Hellmeyer L, Goettsch C, Schoppet M, Hofbauer LC. Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway. J Bone Miner Res 2008, 23:750-758. 10.1359/jbmr.080203, 18251702.
19. Benad P, Rauner M, Rachner TD, Hofbauer LC. The anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1. Cancer Lett 2011, 312:101-108. 10.1016/j.canlet.2011.08.006, 21899945.
20. Just I, Wilm M, Selzer J, Rex G, von Eichel-Streiber C, Mann M, Aktories K. The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. Biol Chem 1995, 270:13932-13936.
21. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, Shaughnessy JD. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009, 113:517-525. 10.1182/blood-2008-03-145169, 2628360, 18687985.
22. Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkotzamanidou M, Terpos E. Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opin Ther Targets 2009, 13:839-848. 10.1517/14728220903025770, 19530987.
23. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011, 377:1276-1287. 10.1016/S0140-6736(10)62349-5, 3555696, 21450337.
24. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011, 8:357-368.
25. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005, 65:7554-7560.
26. Hall CL, Zhang H, Baile S, Ljungman M, Kuhstoss S, Keller ET. p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1. Cancer Res 2010, 70:9916-9926. 10.1158/0008-5472.CAN-10-0440, 3059079, 21098705.
27. Mikheev AM, Mikheeva SA, Maxwell JP, Rivo JV, Rostomily R, Swisshelm K, Zarbl H. Dickkopf-1 mediated tumor suppression in human breast carcinoma cells. Breast Cancer Res Treat 2008, 112:263-273. 10.1007/s10549-007-9867-2, 18157634.
28. Qiao L, Xu ZL, Zhao TJ, Ye LH, Zhang XD. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett 2008, 269:67-77. 10.1016/j.canlet.2008.04.032, 18571836.
29. Zhou XL, Qin XR, Zhang XD, Ye LH. Downregulation of Dickkopf-1 is responsible for high proliferation of breast cancer cells via losing control of Wnt/beta-catenin signaling. Acta Pharmacol Sin 2010, 31:202-210. 10.1038/aps.2009.200, 20139903.
30. Thudi NK, Martin CK, Murahari S, Shu ST, Lanigan LG, Werbeck JL, Keller ET, McCauley LK, Pinzone JJ, Rosol TJ. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate 2011, 71:615-625. 10.1002/pros.21277, 3025080, 20957670.
31. Canalis E. Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab 2010, 95:1496-1504. 10.1210/jc.2009-2677, 2853988, 20375217.
32. Rachner TD, Singh SK, Schoppet M, Benad P, Bornhäuser M, Ellenrieder V, Ebert R, Jakob F, Hofbauer LC. Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 2010, 287:109-116. 10.1016/j.canlet.2009.06.003, 19577359.
33. Ebert R, Zeck S, Meissner-Weigl J, Klotz B, Rachner TD, Benad P, Klein-Hitpass L, Rudert M, Hofbauer LC, Jakob F. Krüppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells. Bone 2012, 50:723-732. 10.1016/j.bone.2011.11.025, 22166808.
34. Rachner TD, Göbel A, Junker M, Hötzel J, Benad-Mehner P, Hadji P, Hofbauer LC. Regulation of VEGF by mevalonate pathway inhibition in breast cancer. J Bone Oncol 2013, 2:110-115.
35. Coleman RE, Allan L, Luis C, Cook RJ, Ker-Ai L, Fred S, Brown JE, Evangelos T, Major PP, Norio K, Matthew S, Jean-Jacques B. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features - an exploratory analysis of placebo-controlled trials. J Bone Oncol 2013, 2:70-76.